Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer

Inclusion Criteria: * Signed the written informed consent form and voluntarily participate in the study. * Pathohistologically confirmed colon adenocarcinoma with cT3c stage or above. * Aged 18 to 80 years, regardless of gender. * The lower edge of the tumor is more than 10 cm from the anus. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Sufficient bone marrow, liver, kidney and coagulation functions assessed by laboratory tests (in accordance with the local laboratory reference range). * No previous anti-tumor treatment for the current colon cancer (including radiotherapy, chemotherapy, surgery, etc.). * No pregnancy or lactation for female patients; male patients agree to take effective contraceptive measures during the study. Exclusion Criteria: * Previous anti-tumor treatment for the current colon cancer. * Previous use of PCSK9 inhibitors or PD-1/PD-L1 inhibitors. * Active autoimmune diseases or a history of autoimmune diseases. * Receiving immunosuppressant or systemic glucocorticoid therapy (except for local low-dose glucocorticoid use). * Active infection requiring systemic anti-infective treatment. * Severe cardiovascular diseases (e.g., severe hypertension, myocardial infarction, heart failure, etc.). * Fasting LDL-C \<1.0 mmol/L (39 mg/dL), only excluding extremely low levels (suggestive of cachexia/severe hepatic disease) * Complicated primary tumor (e.g., tumor perforation, intestinal obstruction without relief after intervention). * Pregnant or lactating women. * Other conditions that the investigator deems unfit for participation in the study (e.g., poor compliance, severe organ dysfunction, etc.).